Latest Observability News

Enova Mining confirms significant rare earth mineralisation at its East Salinas Project in Brazil, with rock chip assays reaching up to 2.17% TREO and elevated NdPr oxide ratios. The company is poised to commence diamond drilling to test these promising targets.

NIB Holdings Limited has announced a fully franked ordinary dividend of AUD 0.16 per share for the half-year ending June 2025, accompanied by a Dividend Reinvestment Plan offering.

Wildcat Resources has significantly extended the lithium-bearing pegmatites at its Bolt Cutter Central discovery near Tabba Tabba, with diamond drilling revealing a down-dip extension of over 700 metres. The discovery remains open in all directions, underpinning a promising exploration pipeline.

The Federal Court has approved the transfer of Centrex Limited’s shares to PRL Global, marking the end of Centrex’s external administration and a new chapter as a PRL subsidiary.

Cadence Capital Limited reported a $6.3 million profit and a 3.4% fund gain for FY25, driven by strong gold sector performance. The company announced a 3.0 cent final dividend with a dividend reinvestment plan and on-market buy-back.

The ASX has formally warned Truscott Mining Corporation that its current operations may not meet listing requirements, giving the company six months to demonstrate compliance or face suspension.

Prominence Energy Limited has secured a pivotal natural hydrogen exploration license in South Australia, marking a major step forward for its Gawler Hydrogen Project and positioning it among the state’s leading clean energy explorers.

Nimy Resources has identified three key conductive plates near a major magnetic anomaly at its Masson discovery, suggesting a significant extension of copper-nickel mineralisation at depth within the Mons Project, WA.

Qube Holdings Limited has announced a fully franked ordinary dividend of AUD 0.057 per share for the six months ending June 2025, signaling steady shareholder returns amid a stable operational period.

Octava Minerals reports impressive initial bioleaching recoveries of critical rare earth elements and lithium from its Byro Project, highlighting a promising, low-cost extraction pathway.

Invion Limited secures a pivotal FDA Orphan Drug Designation for its lead candidate INV043, targeting anal cancer with promising preclinical results and a fast-tracked development path.

LTR Pharma’s intranasal ED treatment SPONTAN achieves peak effect up to five times faster than oral tablets, according to new peer-reviewed clinical data published in a leading European journal.